VTYX Stock Price, Ventyx Biosciences, Inc. Quote, Chart

Market Summary

USD4.28-0.07

Delayedas of 24 Apr 2024, 03:06 pm

-1.61%

VTYX Stock Price

View Fullscreen

VTYX RSI Chart

VTYX Valuation

Market Cap

257.7M

Price/Earnings (Trailing)

-1.34

Price/Free Cashflow

-1.54

VTYX Price/Earnings (Trailing)

VTYX Profitability

Return on Equity

-79.11%

Return on Assets

-69.49%

Free Cashflow Yield

-64.81%

VTYX Fundamentals

VTYX Earnings

Earnings (TTM)

-193.0M

Earnings Growth (Yr)

-32.77%

Earnings Growth (Qtr)

13.46%

Breaking Down VTYX Revenue

52 Week Range

4.2240.58

(Low)(High)

Last 7 days

-8.6%

Last 30 days

-35.1%

Last 90 days

121.9%

Trailing 12 Months

-88.9%

How does VTYX drawdown profile look like?

VTYX Financial Health

Current Ratio

11.87

VTYX Investor Care

Shares Dilution (1Y)

4.26%

Diluted EPS (TTM)

-3.3

Tracking the Latest Insider Buys and Sells of Ventyx Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 12, 2024	nsv partners iii lp	sold	-	-	-695,339	-
Apr 12, 2024	subramaniam somu	sold	-	-	-695,339	-
Apr 02, 2024	nuss john	sold	-8,921	5.4034	-1,651	chief scientific officer
Apr 02, 2024	auster martin	sold	-7,591	5.4035	-1,405	chief financial officer
Apr 02, 2024	krueger christopher w	sold	-8,921	5.4036	-1,651	chief business officer
Apr 02, 2024	mohan raju	sold	-23,299	5.4034	-4,312	ceo and president
Mar 28, 2024	mohan raju	acquired	-	-	11,843	ceo and president
Mar 28, 2024	auster martin	acquired	-	-	4,531	chief financial officer
Mar 28, 2024	krueger christopher w	acquired	-	-	4,531	chief business officer
Mar 28, 2024	nuss john	acquired	-	-	4,531	chief scientific officer

Which funds bought or sold VTYX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	MetLife Investment Management, LLC	sold off	-100	-862,728	-	-%
Apr 19, 2024	NORDEN GROUP LLC	new	-	58,770	58,770	-%
Apr 19, 2024	Cutler Group LLC / CA	reduced	-21.74	4,000	9,000	-%
Apr 11, 2024	Fortitude Family Office, LLC	added	1,401	7,128	7,348	-%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	new	-	2,129	2,129	-%
Apr 05, 2024	GAMMA Investing LLC	added	160	281	330	-%
Apr 05, 2024	CWM, LLC	new	-	4,000	4,000	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	12.00	12.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	40.53	-83,232,000	9,242,550	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	68.71	-49,375,700	6,732,180	-%

Are Funds Buying or Selling VTYX?

Are funds buying VTYX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VTYX

No. of Funds

Unveiling Ventyx Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 04, 2024	flynn james e	5.03%	3,542,000	SC 13G
Mar 21, 2024	cormorant asset management, lp	5.21%	3,670,000	SC 13G
Mar 13, 2024	nsv investments i, l.p.	7.1%	5,004,071	SC 13D/A
Mar 08, 2024	nsv investments i, l.p.	8.5%	5,004,071	SC 13D/A
Feb 23, 2024	point72 asset management, l.p.	5.0%	2,977,868	SC 13G
Feb 14, 2024	citadel advisors llc	5.9%	6	SC 13G/A
Feb 13, 2024	vanguard group inc	6.34%	3,741,925	SC 13G
Jan 29, 2024	blackrock inc.	6.5%	3,814,531	SC 13G
Jan 29, 2024	tang capital partners lp	5.2%	3,100,000	SC 13G
Dec 11, 2023	fmr llc	-	0	SC 13G/A

Recent SEC filings of Ventyx Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 09, 2024	S-3	S-3
Apr 05, 2024	8-K	Current Report
Apr 04, 2024	SC 13G	Major Ownership Report
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 02, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Ventyx Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Ventyx Biosciences, Inc. News

Latest updates

Ventyx Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-13.7%	278	322	349	389	371	420	262	278	291	149	-
Current Assets	-14.2%	264	308	347	387	331	418	252	258	263	146	0.00
Cash Equivalents	-8.9%	52.00	57.00	52.00	64.00	65.00	263	45.00	42.00	71.00	69.00	0.00
Net PPE	11.1%	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Liabilities	-11.3%	34.00	38.00	21.00	18.00	18.00	37.00	19.00	19.00	12.00	12.00	31.00
Current Liabilities	-15.0%	22.00	26.00	20.00	17.00	16.00	36.00	18.00	18.00	12.00	12.00	1.00
Shareholder's Equity	-14.0%	244	284	328	372	354	384	243	259	279	-	-
Retained Earnings	-12.6%	-419	-372	-318	-265	-226	-191	-160	-140	-117	-100	-32.50
Additional Paid-In Capital	1.0%	663	657	647	637	581	576	405	401	397	12.00	2.00
Shares Outstanding	0.5%	59.00	59.00	59.00	58.00	57.00	52.00	51.00	51.00	50.00	3.00	2.00
Float	-	-	-	1,300	-	-	-	385	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-49.0%	-51,655	-34,664	-49,282	-30,921	-47,264	-23,989	-14,792	-12,726	-14,687	-11,041	-9,903	-3,019	-	-
Share Based Compensation	-23.3%	6,145	8,008	7,868	6,567	4,828	4,167	4,131	3,444	1,393	969	288	80.00	-	-
Cashflow From Investing	18.6%	46,125	38,891	34,819	-18,895	-140,840	64,162	18,250	-16,503	-143,090	-73,163	-11.00	1,899	-	-
Cashflow From Financing	-64.0%	585	1,625	2,473	48,646	-10,355	177,792	249	86.00	159,582	50,379	56,725	56,865	-	-

VTYX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development (includes related party amounts of $1,023 and $883, respectively)	$ 175,767	$ 87,738
General and administrative	32,227	25,398
Total operating expenses	207,994	113,136
Loss from operations	(207,994)	(113,136)
Other (income) expense:
Interest income	(15,074)	(4,669)
Other (income) expense	42	(41)
Total other (income) expense	(15,032)	(4,710)
Net loss	(192,962)	(108,426)
Net Income (Loss)	(192,962)	(108,426)
Unrealized gain (loss) on marketable securities	1,121	(1,023)
Foreign currency translation	(48)	(42)
Comprehensive loss	$ (191,889)	$ (109,491)
Net loss per share attributable to common shareholders, basic	$ (3.3)	$ (2.07)
Net loss per share attributable to common shareholders, diluted	$ (3.3)	$ (2.07)
Shares used to compute basic net loss per share attributable to common shareholders	58,542,974	52,471,003
Shares used to compute diluted net loss per share attributable to common shareholders	58,542,974	52,471,003

VTYX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 51,579	$ 64,819
Marketable securities	200,641	253,122
Prepaid expenses and other assets	12,125	12,747
Total current assets:	264,345	330,688
Property and equipment, net	762	407
Operating lease right-of-use assets	11,509	1,537
Marketable securities		38,672
Restricted cash	975
Other long-term assets	102	96
Total assets	277,693	371,400
Current liabilities
Accounts payable	5,756	6,433
Accrued expenses	15,508	9,514
Current portion of operating lease liabilities	1,001	412
Total current liabilities	22,265	16,359
Operating lease liabilities, net of current portion	11,505	1,146
Total liabilities	33,770	17,505
Commitments and contingencies (Note 7)
Stockholders' equity:
Common stock, $0.0001 par value; 900,000,000 shares authorized at December 31, 2023 and December 31, 2022; 59,252,349 and 57,025,847 shares issued at December 31, 2023 and December 31, 2022, respectively; 59,239,113 and 56,980,845 shares outstanding at December 31, 2023 and December 31, 2022 respectively	6	6
Additional paid-in capital	663,154	581,237
Accumulated other comprehensive loss	(50)	(1,123)
Accumulated deficit	(419,187)	(226,225)
Total stockholders' equity	243,923	353,895
Total liabilities and stockholders' equity	$ 277,693	$ 371,400

About Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

CEO	Dr. Raju S. Mohan Ph.D.
WEBSITE	https://ventyxbio.com
INDUSTRY	Biotechnology
EMPLOYEES	91

Ventyx Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Ventyx Biosciences, Inc.? What does VTYX stand for in stocks?

VTYX is the stock ticker symbol of Ventyx Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ventyx Biosciences, Inc. (VTYX)?

As of Tue Apr 23 2024, market cap of Ventyx Biosciences, Inc. is 257.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VTYX stock?

You can check VTYX's fair value in chart for subscribers.

What is the fair value of VTYX stock?

You can check VTYX's fair value in chart for subscribers. The fair value of Ventyx Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ventyx Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VTYX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ventyx Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether VTYX is over valued or under valued. Whether Ventyx Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Ventyx Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VTYX.